Company / Capital Expenditures
Tempest Therapeutics, Inc. Capital Expenditures History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$5.2M
FY2017
5-year range
$719.0K / $5.2M
FY2015-FY2017
Trend
+86.5%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $719,000 to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2017.
Improved from $719,000 to $5M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, capital expenditures increased 86.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $5.2M | +86.5% |
| FY2016 | $2.8M | +290.0% |
| FY2015 | $719.0K | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026